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ABSTRACT 
Background and Aims 
Predicting survival in decompensated cirrhosis (DC) is important in decision making for liver 
transplantation and resource allocation. We investigated whether high-resolution metabolic 
profiling can determine a metabolic phenotype associated with 90-day survival.  
Methods 
248 subjects underwent plasma metabotyping by 
1
H nuclear magnetic resonance (NMR) 
spectroscopy and reversed-phase ultra-performance liquid chromatography coupled to time-of-
flight mass spectrometry (UPLC-TOF-MS; DC: 80-derivation set, 101-validation; stable cirrhosis (CLD) 
20 and 47 healthy controls (HC)).  
Results 
1
H NMR metabotyping accurately discriminated between surviving and non-surviving patients with 
DC. The NMR plasma profiles of non-survivors were attributed to reduced phosphatidylcholines and 
lipid resonances, with increased lactate, tyrosine, methionine and phenylalanine signal intensities. 
This was confirmed on external validation (area under the receiver operating curve [AUROC] = 0.96 
(95% CI 0.90-1.00, sensitivity 98%, specificity 89%). UPLC-TOF-MS confirmed that 
lysophosphatidylcholines and phosphatidylcholines [LPC/PC] were down-regulated in non-survivors 
(UPLC-TOF-MS profiles AUROC of 0.94 (95% CI 0.89-0.98, sensitivity 100%, specificity 85% [positive 
ion detection])). LPC concentrations negatively correlated with circulating markers of cell death 
(M30 and M65) levels in DC. Histological examination of liver tissue from DC patients confirmed 
increased hepatocyte cell death compared to controls. Cross liver sampling at time of liver 
transplantation demonstrated that hepatic endothelial beds are a source of increased circulating 
total cytokeratin-18 in DC 
Conclusion 
Plasma metabotyping accurately predicts mortality in DC. LPC and amino acid dysregulation is 
associated with increased mortality and severity of disease reflecting hepatocyte cell death. 
237 words 
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INTRODUCTION 
The global incidence of cirrhosis is rising rapidly, owing to an increased prevalence of alcohol-related 
liver disease, non-alcoholic fatty liver disease, and viral hepatitis [1]. Patients with cirrhosis are 
prone to decompensation, requiring hospital treatment and can progress to acute on chronic liver 
failure (ACLF)[2] requiring admission to intensive care with an associated high short-term mortality 
and significant economic cost [3].  
Several methods of outcome prediction in cirrhosis are currently used. The Model for End Stage Liver 
Disease (MELD) is the most commonly applied and is used for listing and prioritisation in liver 
transplantation throughout the world. Despite the success of MELD, several limitations exist 
concerning the reproducibility of prothrombin time measurement and the limitations of 
creatinine[4] as a marker of renal function in patients with cirrhosis. The performance of MELD for 
outcome prediction is best in patients with stable cirrhosis, but is less accurate for patients with 
acute-on-chronic liver failure (ACLF) [5]. Therefore organ failure based scores such as the recently 
developed CLIF-SOFA (chronic liver failure-sequential organ failure assessment) score have been 
developed [2, 6].  
Exploratory metabolic profiling or metabotyping involves untargeted measurements of low 
molecular weight (<1kDa) compounds using nuclear magnetic resonance (NMR) spectroscopy or 
mass spectrometry (MS) in biofluids or tissues [7]. The response of complex spectral data is then 
assessed using multivariate statistical techniques[8] to determine which metabolites or metabolite 
combinations most accurately describe differences seen between classes (control or diseased 
cohorts or a state pre- or post-intervention (e.g. drug treatment)). 
 Since the metabolic profile is typically comprised of hundreds or thousands of signals depending on 
the technique, it is, potentially, a highly valuable methodology in delivering personalised healthcare 
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[9], namely highly discriminant prediction of response or diagnostic accuracy. The use of pre-
interventional phenotypes to predict the outcome of intervention based on mathematical modelling 
is termed "pharmacometabonomics"[10] and the approach has been widely used to predict drug 
metabolism[11] and outcomes of cancer therapy, toxicity[12] and safety. 
Metabolic profiling has been applied in inflammatory bowel disease[13, 14], hepatocellular 
carcinoma [15, 16] and to a limited extent, liver failure [17]. The metabolites detected by NMR 
reflect a number of roles of the liver in glucose, lipid, amino acid and urea metabolism and these 
have been investigated in ALF by proof-of-principle measurements [17, 18] and metabolic 
phenotypes specific to patients with minimal hepatic encephalopathy (MHE)[19] or high MELD 
score[20] . 
Liver failure secondary to hepatitis B has  been characterized using mass spectrometry (MS) in 
tandem with either gas chromatography (GC-MS) or liquid chromatography (LC-MS) [21]. Decreases 
in plasma glycerophosphocholine and phosphatidylcholine (PC) levels occur [22], and are common 
markers between different aetiologies of cirrhosis [23, 24]. Apoptosis of hepatic endothelial beds 
may be responsible for this lipid dysregulation. Higher levels of circulating cell death markers have 
been demonstrated in ALF[25, 26], and recently in decompensated cirrhosis (DC) and ACLF [27]. No 
studies have assessed how profiling could prognosticate and none uses a combination of 
technologies to develop a global overview of the metabolic signature of poor survival in DC.  
In this study, we metabotype  plasma in patients with DC to 1) determine and validate a  
1
H NMR 
metabotype of 90-day mortality which we  hypothesise could be more accurate than MELD or CLIF-
SOFA , and 2) characterise the lipids of the 
1
H NMR profile by UPLC-TOF-MS. 
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MATERIALS AND METHODS 
 
Patients and sample collection 
Between December 2008 and January 2011, 80 patients with DC referred to the Institute of Liver 
Studies, Kings College Hospital, London were recruited and followed for 90 days. Cirrhosis was 
defined by at least two compatible diagnostic tests from the following: liver biopsy (fibrosis grade 5 
or more), radiologic (ultrasound, computed tomography or magnetic resonance imaging), clinical 
(presence of hepatocellular jaundice/ascites/hepatic encephalopathy) or biochemical 
(hyperbilirubinaemia, prolonged prothrombin time and/or thrombocytopaenia) to provide evidence 
of cirrhosis. Outcome was defined as either spontaneous survival or death/transplantation. Here, we 
define decompensation as an acute episode of variceal bleeding, jaundice, encephalopathy, ascites, 
sepsis or renal dysfunction requiring hospital admission. The study was approved by the local ethics 
committee (#08/H0702/74) and patients, or their nominee gave written, informed consent within 48 
hours of presentation  Exclusion criteria were presence of hepatocellular carcinoma, non-hepatic 
malignancy, non-cirrhotic portal hypertension, chronic liver disease but not cirrhotic and acute liver 
failure. Liver ICU admission was offered to patients if deemed appropriate by the referring 
hepatologist and/or intensivist. All patients were managed following standard evidence-based 
protocols by a specialist multidisciplinary team [28, 29].  
 
Blood was drawn within 24 hours of admission to hospital into lithium heparin-containing vacuum 
tubes (BD Vacutainer, BD, Franklin Lakes, NJ, USA) and centrifuged at 12000 g for 10 min within 1 hr 
of sample collection. Plasma aliquots were stored immediately at -80
o
C until further analysis. Data 
collected at time of sample collection were age, gender, aetiology of cirrhosis, past medical history, 
medication use, dietary history and 72 hour dietary recall, alcohol and recreational drug use, recent 
exercise history, bedside physiology and blood biochemistry. The Child Pugh Score (CPS)[30]  
MELD[31] , UKELD [32], CLIF-SOFA[2], CLIF AD[33] and CLIF-C ACLF[6] scores  were calculated from 
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data taken on the same day as blood was drawn for metabolic profiling.  Twenty patients with stable 
cirrhosis and 20 age- and sex-matched healthy controls with no history of liver disease, excess 
alcohol or recreational drug use, or hepatotoxic or over the counter medication usage were also 
enrolled following written, informed consent (REC #09/H0712/82). From December 2011 to January 
2015 a further validation cohort of 101 patients (in two cohorts of 59 and 42 respectively) 
hospitalized with DC and 27 healthy controls were recruited. The primary outcome was 90 day 
survival. 
 
NMR data acquisition and processing 
 
Plasma aliquots were thawed to room temperature. Aliquots of 200 µL plasma were added to 400 µL 
of a solution containing 0.9% NaCl and D20 as previously described[34]. This was centrifuged at 
12000 g for 10 minutes and 550 µL of supernatant placed into 5mm NMR tubes (Norell, Landisville, 
NJ, USA). Data were acquired in a random, blinded order on a Bruker Avance
TM
 spectrometer (Bruker 
GmbH, Rheinstetten, Germany) with a 5mm TXI probe operating at 600.13MHz and 300K. Data were 
acquired using a 1D technique using a standard pulse sequence with presaturation of the water 
resonance and Carr-Purcell-Meiboom-Gill (CPMG) spin echo sequences to attenuate the broader 
peaks arising from lipids and proteins, as described in Supplementary Methods along with pre-
processing techniques.  
 
UPLC-TOF-MS data acquisition and processing  
 
Plasma aliquots were thawed to room temperature. 50 µL of plasma were added to 150 µL of ice 
cold 100% methanol, vortexed briefly, and kept at -20
o
C for 20 minutes. Following 10 min of 
centrifugation at 12000 g, 170 µL of supernatant was transferred to Eppendorf™ containers 
(Eppendorf, Stevenage, UK). The supernatants were dried during 90 minutes of centrifugation under 
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vacuum at 40oC(Savant SpeedVac, ThermoScientific, Asheville, NC, USA). Dry material was 
suspended in 120µL of high purity water (UpS grade, Romil Ltd, Cambridge, UK) and sonicated for 30 
minutes. One-hundred µL of each sample were added in a random order to a well in a 96-well plate 
while 20µL were reserved from each to make a quality control (QC) sample. Samples were then 
transferred to the sample manager of a Waters Acquity UPLC system (Waters Corporation, Milford, 
MA, USA) maintained at 4
o
C. Reversed-phase chromatography was conducted using a gradient from 
acidified water to acidified methanol as detailed with MS conditions in Supplementary Material.  
Extraction of features detected by mass spectrometry across the entire sample set was performed 
using XCMS software[35]operating in the R computing environment.  A data matrix of samples 
analysed vs. detected features and corresponding intensity values was produced and analysed by 
multivariate analysis using SIMCA P software (v 12.0.1 Umetrics AB, Umeå, Sweden).  
 
Multivariate analysis of the plasma spectral profiles  
 
For both NMR and UPLC-TOF-MS data, principal components analysis (PCA) was performed to 
visualise any inherent clustering and identify outliers. Orthogonal projection to latent structure 
(OPLS) analysis was performed to maximise class differences while minimising variability unrelated 
to class. The R2 value was calculated to give a measure of the goodness-of-fit or amount of variability 
explained by the model.  A cross-validated Q
2
 statistic (leave-one-out algorithm) was calculated as a 
quantitative measure of the predictability of the model for the Y variable. The cross-validated-
analysis-of-variance (CV-ANOVA) statistic corresponds to a null-hypothesis of equal predictive 
residuals between the models under investigation (p<0.05 suggests the model is superior to one 
chosen at random). Sensitivity and specificity were calculated from the cross validated Y-predicted 
variable. The S-line and S-plot loadings (displaying correlation versus covariance of spectral 
variables) was used to determine the metabolites contributing to class separation for NMR and 
UPLC-MS data respectively.  AUROC comparison was by the Hanley-McNeill method. Univariate 
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comparison of plasma levels of metabolites was performed by one way ANOVA within MedCalc 
v12.1.4 (MedCalc Software, Mariakerke, Belgium). 
 
Measurements of cell death activity 
Plasma levels of total (un-cleaved) cytokeratin-18 (M65) and caspase-cleaved cytokeratin-18(M30) 
were quantified with commercially available ELISAs (Peviva AB, Bromma Sweden), previously 
validated in clinical trials and used according to manufacturer’s instructions as described elsewhere 
[36]. Levels were taken in patients with DC, stable chronic liver disease (CLD) and healthy controls 
(HC). To determine the role of the liver in cell death activity, M30 and M65 levels were also 
measured in 7 patients with DC at the time of liver transplantation prior to hepatectomy. 
Liver Samples and Immunohistochemistry.  
Explant liver tissue was available in 6 patients undergoing OLT for DC. Background liver from liver 
resection specimens containing metastatic adenocarcinoma from colo-rectal primaries (n = 4) served 
as normal control tissue. Liver tissue from a patient with post-liver transplant recurrent HCV 
infection was used as a positive control. Negative controls were obtained by omitting the primary 
antibody. Tissue samples were taken for diagnostic histological examination and formalin fixed, 
paraffin-embedded (FFPE), and stained with H & E using a standard procedure. FFPE tissue was cut 
at 4 μm and serial sections were picked up on poly-l-lysine coated slides which were manually 
stained using the M30 CytoDEATH primary antibody (product number 12140322001, Roche, UK; 
dilution 1:10). 
M30 enzymatic immunohistochemistry are described in the Supplementary Methods 
 
  
  
 
 11 
RESULTS 
Eighty patients (median age 55(23-75) years, 60 male) comprised the derivation cohort (Table 1). 
Sixty two patients spontaneously survived. In keeping with other reports of outcome in these 
groups, non-survivors exhibited a higher MELD, UKELD and CPS and were associated with higher 
levels of requirements for organ support therapies. Aetiology was not associated with mortality. 
Thirty seven patients met criteria for ACLF at the time of recruitment (15 patients with ACLF grade 1, 
17 with ACLF grade 2 and 5 with ACLF grade 3). The remainder (43) did not meet CANONIC criteria 
for ACLF. 
NMR spectroscopic multivariate analysis 
Comparisons between controls and patients with cirrhosis 
Examples of 1H NMR spectral data for plasma are shown in Figure S1. Clear differences can be seen 
in the glucose, lipid and lactate resonances between controls and patients with liver disease. PCA 
comparing controls with liver disease patients in a 3 component model gave an R
2
X statistic of 0.75 
with a Q
2
Y of 0.54 (Figure S2). OPLS-DA analysis gave similar robust differentiation of the NMR 
spectral profile (R2X=0.67, R2Y=0.75, Q2Y=0.59, CV-ANOVA 10-23, sensitivity 97%, specificity 100%). 
Resonances increased in patients with cirrhosis were lactate, glucose, methionine and pyruvate, 
while those reduced in patients with cirrhosis were lipid, choline and phosphocholine resonances 
(see Table 2 and Supplementary material). OPSLDA modelling accurately discriminated patients with 
and without ACLF profile (R
2
X=0.25, R
2
Y=0.49, Q
2
Y=0.38, CV-ANOVA 10
-9
, sensitivity 83%, specificity 
90%) but did not discriminate by aetiology. 
Outcome prediction in patients with DC 
When 90-day survival was used as the class variable within the cohort of patients with DC, a 
discriminant model was produced (3 component OPLS-DA (R
2
X = 0.57, R
2
Y = 0.46, Q
2
Y = 0.39) with 
100% sensitivity and 85%, CV-ANOVA 10
-6 
Figure 1). Higher levels of lactate, tyrosine, methionine 
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and phenylalanine were found in patients with poor outcome, whereas lower levels of the lipid 
resonances (VLDL, LDL) and particularly the choline/phosphocholine resonances at δ 3.22 were 
demonstrated. The resonance at δ 3.22 contains peaks attributable to both choline and the 
associated phosphocholine macromolecule and therefore reversed-phase UPLC-TOF-MS was 
performed for detailed metabolite characterisation (see below). 
External validation of NMR profiling as predictive of hospital survival 
In a separate cohort of 59 patients with DC (median age 56 (43-65), 54% male, 14D; 45 SS, see 
Supplementary Material) the 3 component NMR profile developed on the training set was used to 
predict outcome in this fully external validation cohort. The outcome prediction accuracy was again 
excellent with a sensitivity of 98 (87-100) %, specificity 89(67-99) %, positive likelihood ratio 9(3-34), 
negative likelihood ratio 0.03(0.004-0.2), AUROC 0.96 (0.90-1.00) (Figure 2). In a further validation 
cohort both the differences between patients with cirrhosis (n=42) and controls (n=27) and 
discriminatory ability for predicting 90-day mortality were confirmed (see Supplementary data). 
By limiting the metabolites used for prediction to those with a variable importance of more than 
unity a simplified metabolite array of (GPC, lactate, LDL, phenylalanine, methionine, pyruvate, 
glucose and tyrosine) retained discriminatory accuracy - R2X 0.61 R2Y 0.41 Q2Y 0.15, CV ANOVA 
p=0.02 , AUROC 0.86, sensitivity 92%, specificity 85%). 
Characterisation of lipids by UPLC-TOF-MS multivariate analysis 
In the dataset resulting from positive ion formation (examples in Figure 2), accurate discrimination 
between patients with cirrhosis and healthy controls was attained with PCA (3 component model 
R
2
X=0.53, Q
2
Y=0.51) and confirmed on subsequent OPLS-DA (3 component model - R
2
X=0.52, 
R
2
Y=0.67, Q
2
Y=0.42, sensitivity 85%, specificity 97%, CV-ANOVA 3 x 10
-14
).  
A two component model was used for discrimination between survivors and non-surviving patients 
with decompensated cirrhosis, producing a valid model for discrimination of survival (Figure 1, 
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R2X=0.47, R2Y=0.54, Q2Y=0.40, AUROC 0.94, sensitivity 100%, specificity 85%, CV-ANOVA p=10-8).  
Major discriminatory metabolites are listed in Table S1. A collection of masses related to adducts of 
other lysophosphatidylcholines (LPCs) and phosphatidylocholines (PC) were identified as being 
reduced in non-surviving patients as shown in Table 3, confirming the importance of down-
regulation of a number of LPC/PC species in increasing severity of liver disease and in outcome 
prediction. See Supplementary Results for negative mode ionisation.  
Cell death markers increased in DC and correlate with LPC concentrations 
Levels of M30 were elevated in both CLD and DC compared with HC (Figure 4). Similarly, the plasma 
levels of M65 were also highest in DC patients, compared to CLD and HC. M30/M65 ratios were 
lowest in DC, compared to other groups. M30 and M65 were correlated with MELD score (M30 v 
MELD r=0.40, p=0.002; M65 v MELD r=0.39, p=0.004). On OPLS modelling M65 levels correlated 
negatively with the LDL (pcorr -0.85) and PC (pcorr -0.74) resonances on 
1
H NMR and correlated 
positively with alanine (0.51), methionine (0.49), tyrosine (0.66) and phenylalanine (0.74, p<0.001 
for all correlations model CV ANOVA p=0.004). M30 and the apoptotic index M30/M65 did not 
produce valid OPLS models with the NMR profile. 
Of the identified lipids on UPLCMS, LPC (16:0) was negatively correlated with M30 (r=-0.30,p=0.010) 
and M65 (r=-0.39,p=0.002) levels and also predicted hospital survival (AUROC 0.76 (95%CI 0.66-
0.84),p<0.001).  
M65 levels performed less well at outcome prediction (AUROC 0.66 (95%CI 0.54-0.76)p=0.02). M30 
and M30/M65 ratio were not independently associated with outcome. 
Cross liver sampling demonstrates hepatic endothelial beds as source of total cytokeratin-18 in DC 
Blood sampling from the systemic artery, portal and hepatic veins at the time of liver transplantation 
prior to hepatectomy demonstrated higher levels of M65 in the hepatic vein compared to portal vein 
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(p=0.047) and lower M30/M65 ratios in the hepatic vein, compared to portal vein (p=0.027, see 
Figure 4). 
The quantitative analysis of apoptotic cells in the control and DC groups on the M30-stained slides 
revealed a significant increase in apoptotic cell numbers in the DC group compared to controls (p= 
0.008). This finding was supported by a similar increase as assessed on the H & E stained slides from 
the same cases (see Figure 4, p=0.002). 
Comparison of outcome prediction abilities of profiling techniques 
The AUROC curves analysis of the metabolic profiling techniques in comparison with accepted 
clinical decision making tools is shown in Table 4 and Supplementary Material. All profiling 
modalities (NMR and in both UPLC-TOF-MS ionization mode) generated Y-prediction scores with 
increased predictive accuracy over CPS, CLIF-SOFA, CLIF AD, CLIF-C ACLF and MELD.  Combining 
clinical scores with metabolic profiling methods gave models with similar accuracy to the metabolic 
profiling techniques and combining CLIF-SOFA (the most accurate clinical scoring system in this 
cohort) with NMR profiling data gave a high degree of accuracy similar but not superior to NMR 
profiling (see Table 4). 
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DISCUSSION 
This study demonstrates that metabolic profiling of plasma in patients with DC can provide both 
highly accurate prognostication and mechanistic insights into the metabolic and cellular 
perturbations of acute decompensation. Circulating levels of LPC/PCs, amino acids and energy 
metabolites combined by multivariate methods in patients who do not survive to hospital discharge 
have a characteristic profile. For the first time we demonstrate metabotyping to be more accurate 
than standard clinically derived prognostic tools although this requires validation in larger datasets.  
The most important metabolite class discovered and validated in these prognostic models was the 
lipid subclass PC/LPC. PC and LPCs have been implicated in malignancies, autoimmune disease, 
inflammation and cell signalling. These lipids regulate cell senescence, liver repair and lipolysis, and 
elicit many immune-modulatory functions including enhancing chemotaxis [37], stimulating 
phagocytosis and upregulating the expression of adhesion molecules [38] and reducing the organ 
injury and dysfunction in septic shock [39].  
Reduced plasma levels of LPCs and PCs occur in murine models of liver injury [40] and human liver 
failure [41] independently of age, gender and diet and in correlation with MELD [42].  Murine models 
[40] of alcohol-related liver injury have demonstrated similar differences in the PC/LPC profile, as in 
our UPLC-TOF-MS results. In particular, the reduction in LPC (16:0/18:0) seen in both our study and 
in previous reports (in both patients with hepatitis B cirrhosis and alcoholic liver disease) suggest 
common lipid derangements correlate with severity of disease and not aetiology.  
No previously reported studies provided a mechanistic insight into how PC/LPC are associated with 
severity of ACLF or outcome. We hypothesised that circulating lipid abnormalities were a reflection 
of cell death, similar to ALF [25]. Cytokeratin-18 fragments in peripheral blood are generated by 
apoptosis and full-length cytokeratin-18 generated by necrosis, and are elevated in a variety of liver 
diseases including NASH and viral hepatitis [43-45]. The commonly used M30 antibody identifies a 
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fragmented form of cytokeratin-18 generated by cleavage of multiple caspases (3,6 and 7). The M65 
antibody allows measurement of all cytokeratin-18 fragments because of loss of cell membrane 
integrity from necrosis and/or apoptosis[46]. Concurrent measurement using the M30 and M65 assays 
allows for the quantification of the relative contributions of apoptosis and necrosis to cell death [46]. 
The M30/M65 ratio is therefore an indicator of the contribution of apoptosis to the total cell death 
activity (expressed by M65).  
 
Our hypothesis proved partly correct with strong negative correlations with total cytokeratin-18 and 
circulating lipids. We demonstrate M30 and M65 levels are increased in patients with DC, compared 
to stable CLD. In ALF, we have previously demonstrated differences in cross-gut and cross-liver levels 
of markers of apoptosis [25]. In contrast, and for the first time, we have demonstrated that the liver 
is a source of total cytokeratin-18 production in DC. This suggests (in conjunction with the strong 
M65 correlations with lipids (both PC and LDL) and amino acids in the 1H NMR spectra) that necrosis 
is also an important process in ACLF. This is interesting in comparison with recent reports of 
apoptosis in ACLF[27] and while we agree that apoptosis is an important mechanism of hepatocyte 
cell death, necrosis may still have an important contribution.  
 
We are not yet in a position to define causality in this relationship, but necrosis may disrupt overall 
lipid production or its release into peripheral blood, while apoptosis may consume LPC as signalling 
molecules, as well as contributing to intrahepatic lipid accumulation. LPCs are implicated in the death 
of a number of endothelial cell types, but in particular of the hepatocyte. In hepatocyte lipoaptosis in 
NASH[47] LPC may be produced from di-acylglycerol in preference to triglyceride production if 
saturated fatty acid (FA) levels are higher than unsaturated FA, or in the presence of pro-apoptotic 
protein signalling. LPC may then generate apoptosis via mitochondrial-induced caspase activation or 
activation of G-protein coupled receptors[47]. Exogenous LPC has also been reported to induce 
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apoptosis [47, 48] of endothelial cells and stimulate inflammatory cells [49] in experimental models of 
sepsis.  
Following experimental hepatectomy, hepatocyte loss and acute liver failure is associated with 
reduction in levels of circulating lipids and marked hepatic lipid accumulation [50]. A number of recent 
studies have suggested that hepatic necrosis is also a hallmark of ACLF [51, 52], but as yet there are 
no human studies that investigate the role of lipids and hepatic necrosis together in ACLF. 
Nevertheless, formation of TAG within the hepatocyte and failure of LPC production from DAG under 
the influence of pro-apoptotic proteins may further reduce circulating LPC levels. Following APAP-
induced hepatic necrosis in rats, dose dependent increases in serum levels of lactate, pyruvate and 
isoleucine are noted with reductions in serum GPC[53]. In methotrexate-induced hepatic necrosis in a 
rat model of NASH using a methionine-choline deficient diet, liver necrosis was associated with higher 
hepatic GPC [54]. 
Further studies at the hepatic level with liver tissue are necessary to define a causal relationship 
between dyslipidaemia and apoptosis/necrosis but both methods of cell death are likely occurring in 
patients with DC. 
We also demonstrated the importance of energy metabolites such as lactate and amino acids such 
as tyrosine, phenylalanine and methionine. Hepatic ischaemia and failure to clear (as well as 
increased production of) lactate are well described and lactate is a classic biomarker of mortality in 
hepatology and critical illness when aerobic metabolism is overwhelmed. Increases in aromatic 
amino acids are also well described as ammonia levels rise in conjunction with failure of the urea 
cycle in patients with hepatic encephalopathy and liver failure[55]. However, ammonia alone is a 
poor biomarker of survival in cirrhosis as a number of cofactors including inflammation[56] are 
required to generate high grade HE and contribute to poor outcome. Similarly, the urea rise we see 
in non-survivors in this study is more likely related to failure of renal excretion given the high 
creatinine in patients who do not survive. The combination of these markers with lipids in the 
1
H 
  
 
 18 
NMR gives similar prognostic accuracy as the UPLCMS so choosing between the two methods would 
depend on a number of factors such as cost, reproducibility and familiarity. This is further discussed 
in the Supplementary Material. 
The limitations of this study include its relatively small number of participants. We performed 
sample size analysis, based on previous NMR work in patients with ALF [17], based on a 10% 
improvement in AUROC curve from an estimated MELD AUROC. Although we used a mix of 
aetiologies the metabolic profile associated with severe decompensation and mortality has not been 
shown to be aetiology dependent. Lead-time bias is difficult to fully control in these cohorts, given 
patients present following decompensation at different times and therefore future validation will 
include larger patient numbers at different time points during the evolution of decompensation or 
ACLF.  
Deployment of metabolic profiling techniques to assist clinical decision making would require 
protocols to allow comparison of measurements between centres. While NMR spectrometers would 
represent a significant capital cost for hospitals each spectral acquisition is possible within 30 
minutes. UPLC-MS instruments are more commonplace, with low space requirements and the ability 
to quantify metabolite levels in minutes.  Translating this technology into the clinical setting is 
worthwhile, given the potential advantages of both the global profiling techniques and the 
multivariate statistics [57, 58] to provide highly accurate modelling and a personalized prediction 
system. This kind of step change in outcome prediction performance can be realised via 
collaborations, such as the UK National Phenome Centre and Human Phenome Project[59] and may 
revolutionise approaches to the patient journey based on metabotyping to allow meaningful 
translation for this powerful but underutilised systems biology toolset. 
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Figure Legends 
 
Figure 1: 
1
H NMR and UPLCMS plasma profile models. These multivariate models demonstrate discrimination 
of patients with DC who survive or die A-D) 1H NMR data (A) Principal components analysis (PCA) scores plot 3 
component model R
2
X=0.75 Q
2
=0.54  (B) Orthogonal projection least squares discriminant analysis (OPLSDA) 
scores plot (1+2+0) R
2
X=0.57 R
2
Y=0.46 Q
2
=0.25 (C) permutation analysis (D) S-line loading plot (E-H) UPLCMS 
positive mode data (E) PCA scores plot (3 components) R
2
X=0.54 Q
2
=0.42  (F) OPLSDA scores plot (1+2+0) 
R
2
X=0.52 R
2
Y=0.67 Q
2
=0.42 (G) permutation analysis (H) S-plot loadings. 
1
H NMR peak annotations are as per 
Table 2. 
Figure 2: Comparison of outcome prediction performance by Area Under Receiver Operating Curve (AUROC) 
analysis. AUROC comparisons of CPMG (Carr-Purcell-Meiboom-Gill), NMR (nuclear magnetic resonance), MELD 
(model for end stage liver disease), CLIF-SOFA (chronic liver failure sequential organ failure assessment), 
UPLCMS (ultra-performance liquid chromatography mass spectrometry) 
A) Derivation Cohort CPMG NMR profile (AUROC 0.95(0.90-1), sensitivity 100%, specificity 79%, p<0.001); CLIF-
SOFA - AUROC 0.87(0.77-0.93) sensitivity 78%, specificity 91%, p<0.001); MELD - AUROC 0.81(0.66-0.96), 
sensitivity 78%, specificity 86%, p<0.001); Child-Pugh Score - AUROC 0.87 (0.76-0.98), sensitivity 83%, 
specificity 78%, p<0.001. 
B) Validation Cohort CPMG NMR profile (AUROC 0.96(0.90-1), sensitivity 98%, specificity 84%, p<0.001); CLIF-
SOFA - AUROC 0.93(0.86-0.99) sensitivity 74%, specificity 100%, p<0.001); MELD - AUROC 0.87(0.66-0.96), 
sensitivity 89%, specificity 79%, p<0.001); Child-Pugh Score - AUROC 0.87 (0.76-0.98), sensitivity 80%, 
specificity 79%, p<0.001. 
Figure 3: Analysis of markers of cell death in peripheral blood, across the liver and in correlation with 
metabolic profiling. Panels (A-C): Comparison of markers of cell death in peripheral blood on day 1. DC – 
Decompensated cirrhosis, CLD chronic stable liver disease, HC healthy control. Kruskall Wallis test with Dunns 
test for multiple comparisons (*p<0.05, **p<0.01,***p<0.001,****p<0.0001) Data are expressed as 
mean(SEM).  
(D-F): Total and caspase cleaved cytokeratin-18 levels measured by ELISA from samples taken from the hepatic 
vein (HV), portal vein (PV) and systemic artery (ART) at the time of liver transplant prior to hepatectomy in n=7 
patients. D) M30 levels demonstrating no gradient E) M65 levels demonstrating positive gradient between 
portal and hepatic vein E) M30/M65 ratio demonstrating negative ratio between portal and hepatic veins. All 
M30 and M65 levels are in iU/L (logarithmic scale for D-F, Paired t test NS-non significant *p<0.05)  
(G-I) OPLS modelling of 1H NMR plasma of patients with DC and M65 levels G) OPLS model (1+1+0 
components, R2X = 0.39 R2Y= 0.56 Q2=0.27 CV ANOVA p=0.004) H) permutation test demonstrating validity of 
model I) OPLS S-line loading plot demonstrating correlation with M65 levels and 1H NMR measured 
metabolites in particular LDL, PC (negative correlation), alanine, methionine, phenylalanine and tyrosine 
(positive correlation; peak annotations as for Figure 1 and Table 2). 
Figure 4: Histological analysis of liver tissue. These demonstrate apoptosis in explanted liver tissue from 
control and DC cases. (A) Representative micrograph showing a homogeneous cytoplasmic pattern in a cell 
morphologically similar to acidophilic bodies from H & E stains, in explanted control liver tissue (* intense 
coarse granular cytoplasmic staining pattern of hepatocytes regarded as non-specific staining and excluded 
from the quantitative assessment). (B) Representative micrograph demonstrating homogeneous cytoplasmic 
staining for M30 in cells with morphologic features suggestive of apoptotic bodies (C), on a biopsy from a 
patient with post-transplant recurrent HCV infection. (D-G) Representative micrographs of M30+ apoptotic 
cells and acidophilic bodies on H & E stain in the control and DC groups showing an increased numbers in the 
latter. (H) Enumeration of apoptotic cells in control (n = 4) and DC groups (n = 6), as assessed by enzymatic 
immunohistochemistry and H & E staining. 
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TABLES 
Variable All patients Survivors Non-survivors p-value 
 80 62 18  
Age 55 (23-75) 55(23-75) 51(39-73) 0.955 
Sex (Male:Female) 60:20 54:8 16:2 0.667 
Aetiology 
 
Alcohol 
Viral hepatitis 
Autoimmune 
Non-alcoholic 
steatohepatitis 
Other 
 
 
 
 
43 
8 
16 
8 
 
5 
 
 
 
32 
6 
14 
7 
 
3 
 
 
12 
2 
1 
1 
 
2 
 
 
0.629 
Diabetes(Y:N) 19:61 13:49 4:14 0.381 
     
Serum Na (mmol/L) 137(125-149) 137(125-146) 137(132-149) 0.304 
K (mmol/L) 4.2(2.1-5.5) 4.2(2.1-5.5) 4.0(3.1-4.8) 0.165 
Ct (µmol/L) 85(39-211) 83(39-149) 110(53-211) 0.085 
     
AST (iU/L) 55(22-2848) 54(22-2848) 63(34-510) 0.250 
GGT (U/L) 86(13-1754) 86(15-1754) 85(13-312) 0.349 
Bilirubin (µmol/L) 33(8-511) 30(8-474) 177(27-511) <0.001 
Albumin (g/L) 33(7-48) 34(15-48) 27(7-39) <0.001 
INR 1.4(0.9-14.7) 1.3(0.9-14.7) 1.9(1.3-4.0) <0.001 
     
Haemoglobin (g/L) 11(6.5-16) 11.9(7.7-16) 9.0(6.5-11) <0.001 
WCC (x 109/L) 5.5(1.5-35) 5.0(1.5-35) 9.7(4.2-21) <0.001 
Platelets (x 109/L) 104(34-550) 110(34-550) 78(35-369) 0.046 
     
HE Grade 0 (0-4) 0(0-4) 2.5(0-4) <0.001 
Ammonia (µmol/L) 98(19-268) 98(19-268) 98(44-238) 0.962 
Mechanically 
ventilated(Y:N) 
13:67 6:56 9:9 <0.001 
Vasopressor use(Y:N) 12:68 5:57 8:10 <0.001 
     
ACLF grade (0/1/2/3) 43/15/17/5 40/12/9/1 3/3/8/4 <0.001 
CPS 9(7-13) 8(7-13) 12(7-15) <0.001 
CLIF-SOFA 7(4-18) 7(4-18) 10(5-18) <0.001 
MELD 15 (4-40) 12(4-29) 23(6-40) <0.001 
UKELD 61(43-88) 56(50-68) 75(63-84) <0.001 
Table 1: Demographic, biochemical and physiological details from the derivation study population. 
p-values - χ2 test for categorical variables, Mann Whitney U test for continuous variables. 
Continuous data given as median (range). Abbreviations HE (Hepatic Encephalopathy), INR 
(International Normalised Ratio), WCC (White Cell Count), CPS (Child Pugh Score), MELD (Model for 
End Stage Liver Disease), CLIF-SOFA (Chronic Liver Failure Sequential Organ Failure Assessment) 
UKELD (United Kingdom End Stage Liver Disease)
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 Metabolite Chemical shift 
and 
multiplicity 
HC DC- S DC - D p-value 
(ANOVA) 
p-value 
(DC-D v DC-S) 
        
1 Lipids (mainly 
LDL) 
0.84 (t), 1.2b 
(m) 
29.1(7.4) 19.9(8.14) 22.1(8.20) <0.001 0.002 
2 Lipids (mainly 
VLDL) 
0.87 (t), 1.29 
(m), 1.57 (m) 
38.1(16.7) 26.9(13.7) 26.8(15.0) <0.001 0.220 
3 Isoleucine 0.93 (t), 1.00 
(d) 1.25 (ddd) 
1.20(0.18) 1.02(0.22) 1.10(0.25) 0.001 0.010 
4 Leucine 0.94 (d), 0.95 
(d), 1.70 (m), 
3.73 (m) 
1.10(0.20) 0.91(0.20) 0.93(0.19) <0.001 0.025 
5 Valine 3.6(d), 
2.26(m), 
0.8(d), 1.04(d) 
0.72(0.16) 0.63(0.17) 0.54(0.17) <0.001 0.666 
6 Lactate 4.11(q), 
1.32(d) 
13.2(3.30) 12.9(4.05) 13.8(9.70) <0.001 <0.001 
7 Alanine 1.46(d), 
3.77(m) 
3.14(0.59) 3.00(0.92) 3.50(2.51) 0.595 0.079 
8 N-acetylated 
glycoproteins 
2.06(s) 2.49(0.40) 2.25(0.44) 2.23(0.42)  0.228 
9 Methionine 2.13(s) 1.42(0.71) 1.58(0.57) 2.13(2.53) 0.033 0.019 
10 Pyruvate 2.36(s) 0.46(0.12) 0.60(0.14) 0.59(0.22) <0.001 0.047 
11 Citrate 2.53(d), 
2.66(d) 
   0.023 0.012 
12 Creatinine 3.03(s) 1.06(0.15) 1.16(0.61) 1.23(0.70) 0.236 0.002 
13 Choline 3.19(s) 11.04(3.16) 8.65(2.48) 7.35(3.37) <0.001 <0.001 
14 Phosphocholine 3.22(s) 3.97(1.21) 4.78(1.71) 3.43(1.18) <0.001 <0.001 
15 Glycine 3.55(s) 3.36(1.45) 4.02(1.79) 3.11(1.18) 0.001 0.157 
16 Glucose 3.42(s), 
3.54(dd), 
3.76(m), 
3.84(m), 
5.23(d) 
0.95(0.54) 1.21(0.59) 0.88(0.37) <0.001 0.107 
17 Urea 5.8(s) 1.34(0.45) 2.39(0.56) 4.64(0.78) 0.04 0.002 
18 Tyrosine 7.18(dd), 
6.89(dd) 
0.65(0.22) 3.99(0.88) 5.34(1.32) <0.001 <0.001 
19 Histidine 7.04(s), 
7.74(s) 
1.65(0.45) 1.89(0.65) 2.03(0.76) 0.14 0.453 
20 Phenylalanine 7.32(d), 
7.41(t) 
0.87(0.21) 3.21(0.87) 5.09(1.32) <0.001 <0.001 
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21 Formate 8.45(s) 1.21(0.32) 1.87(0.56) 2.54(.065) 0.379 0.001 
Table 2: Nuclear magnetic resonance (NMR) observed metabolites with intensity (mean (SD), 
arbitrary units) differences associated with decompensated cirrhosis versus controls and those liver 
disease patients with and without poor prognosis with sign of change denoted. The assignment 
numbers as per the annotation in Figure 1. Nuclear magnetic resonance peak multiplicity – s 
(singlet), d(doublet),  t (triplet), m(multiplet), dd( doublet of doublets). LDL(low density lipoproteins); 
p-values one way ANOVA with multiple comparison correction. 
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 RT 
(mins) 
Mass 
(m/z) 
Adduct HC DC-S DC-D 
 
p-value 
(ANOVA) 
p-value 
(DC-S v 
DC-D) 
Compound 
1 12.4 518.3 
496.3 
M+Na 
M+H 
4.56  
(1.27) 
1.72  
(1.71) 
6.80 
(0.87) 
<0.001 <0.001 LPC(16:0)
M,S
 
LPC(16:0) 
2 18.6 758.6 M+H 9.12(1.54) 6.89(2.78) 4.54(3.39) <0.001 <0.001 PC(34:2)
A
 
3 18.9 
 
806.6 
784.6 
M+Na 
M+H 
6.73(0.91) 6.11(1.65) 4.06(2.13) <0.001 <0.001 PC(18:1/18:2)
 M,S
  
4 18.1 804.6 M+Na 5.71(0.69) 3.79(1.46) 2.12(1.34) <0.001 <0.001 PC(18:2/18:2)
 M
 
5 18.6 780.5 M+Na 6.80(0.69) 6.37(1.28) 5.04(1.83) <0.001 <0.001 PC(16:0/18:2)
 M
 
6 16.8 723.5 M+H 3.63(0.80) 1.54(1.10) 1.26(1.23) <0.001 NS PG(20:0/15:0)
 A
 
7 19.8 
 
786.6 
808.5 
M+H 
M+Na 
3.74(0.96) 1.82(0.93) 1.06(0.85) <0.001 <0.001 PC(18:0/18:2)
 M,S
 
8 12.3 542.4 M+Na 1.9(0.4) 1.2(1.0) 0.66(0.44) <0.001 <0.001 LPC(18:2)
 M,S
 
9 17.9 802.5 M+Na 2.79(0.69) 1.18(0.73) 0.53(0.05) <0.001 <0.001 PC(18:2/18:5)
 A
 
10 13.9 381.3 M+Na 16.6 
 (5.75) 
8.80 
 (5.88) 
7.09 (4.96) <0.001 <0.001 Hexadecyl-acetyl 
glycerol
 A
  
11 8.6 568.2 M+H 1.6(0.2) x10
-
2
 
0.29(0.11) 2.45(3.23) <0.001 <0.001 Unknown  
12 19.6 856.5 M+H 1.40(0.45) 0.39(0.04) 0.15(0.01) <0.001 <0.001 PC(22:5/20:4)
 M,S
 
13 19.8 877.6 M+H 0.68(0.096) 0.99(0.02) 0.86(0.02) <0.001 <0.001 PI(37:2)
 A
 
14 18.4 876.6 M+Na 1.39(0.19) 20.1(0.41) 1.72(0.48) <0.001 <0.001 PS (41:4)
 M
 
15 18.7 849.5 M+H 0.47(0.066) 0.73(0.016) 0.74(0.01) <0.001 NS PI(35:2)
 A
 
Table 3: The putative identification (ID) of UPLC-TOF-MS measured metabolites associated with 
cirrhosis and with poor prognosis and intensity differences between classes (mean (SD), arbotrary 
units). LPC - lysophosphatidylcholine, M-H protonated adduct, M-Na sodiated adduct, PC – 
phosphatidylcholine, choline, PG – phosphatidylglycerol ,PI phosphatidylinositol, PS – 
phosphatyidylserine; metabolite identification superscripted-M-MS/MS, S-standard, A-accurate 
mass; p-values one way ANOVA with multiple comparison correction. 
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Outcome 
model 
AUROC Sensitivity/% Specificity/% LR+ LR- 
Derivation 
Cohort 
     
      
MELD 0.81(0.66-0.96) 
 
78(49-95) 86 (75-94) 5.7 (4.3-7.6) 0.3 (0.1-0.8) 
CPS 0.87(0.76-0.98) 
 
83(52-98) 78(65-88) 3.8 (2.8-5.0) 0.2 (0.1-0.8) 
CLIF-SOFA 0.87(0.77-0.93) 78(49-95) 91(82-97) 9.1(4.1-
20.7) 
0.2(0.1-0.6) 
 
CPMG 
NMRS 
0.95 (0.90-1.00) 100 (69-100) 
 
79 (65-90) 4.8 (4.2-5.5) 
 
0 
 
UPLCMS 
ESI+ 
 
0.94 (0.89-0.98) 
 
100 (74-100) 85 (73-93) 6.4 (5.8-7.2) 0 
UPLCMS 
ESI- 
 
0.94 (0.88-0.98) 
 
100 (74-100) 79 (66-88) 4.7 (4.1-5.4) 0 
Validation 
Cohort
∆
 
     
MELD 
 
0.87(0.76-0.98) 87(73-96) 79(54-93) 4.2(1.7-10) 0.16(0.07-0.4) 
CPS 
 
0.87(0.78-0.96) 80(64-91) 79(54-94) 3.8(1.6-9.2) 0.25(0.1-0.5) 
CLIF-SOFA 
 
0.93(0.86-0.99) 74(58-87) 100(82-100) - 0.26(0.2-0.4) 
CLIF AD 
 
0.83 (0.72-0.95) 92(81-98) 68(45-86) 2.9(1.6-5.4) 0.12(0.04-0.3) 
CLIF-C ACLF 
 
0.85(0.74-0.96) 84(71-92) 82(60-95) 4.6(1.9-11) 0.2(0.1-0.4) 
CPMG 
NMRS 
 
0.96(0.90-1.00) 98(87-100) 89(67-99) 9.3(3.2-34) 0.03(0.004-0.2) 
CLIFSOFA+ 
CPMG 
 
0.95(0.89-1.00) 79(63-90) 100(82-100) - 0.21(0.1-0.4) 
 
Table 4: The comparison of Model for End Stage Liver Disease (MELD), Child Pugh Score (CPS) and 
Chronic Liver Failure Sequential Organ Failure Assessment (CLIF-SOFA), CLIF Acute Decompensation 
(CLIF AD) and CLIF Acute on Chronic Liver failure (CLIF C ACLF)  for prediction of hospital survival in 
patients with decompensated cirrhosis in comparison with Y-predicted metabolic profiling strategies 
via NMR and UPLC-TOF-MS (LR – likelihood ratio, Abbreviations - MELD (Model for End Stage Liver 
Disease), CPS (Child Pugh Score), CLIF-SOFA (Chronic Liver Failure Sequential Organ Failure 
Assessment), CPMG (Carr Purcell Meiboom Gill), NMRS (nuclear magnetic resonance spectroscopy), 
UPLCMS ESI (Ultra Performance Liquid Chromatography Mass Spectrometry Electrospray Ionisation), 
∆
1
st
 validation cohort comparison. 
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